Latest News & Updates

Breaking News

  • 4 hours ago

  • Simantini Singh Deo

European Commission Approves Roche’s Lunsumio Subcutaneous For Adults With Relapsed Or Refractory Follicular Lymphoma After Two Or More Prior Therapies
Breaking News
Elicio Therapeutics Appoints Marc J. Wolfgang As Chief Technology Officer, Bringing 30+ Years Of Biopharma Leadership In Cell Therapy, RNA Medicines, And Biologics

Simantini Singh Deo

Other trending news you may like to read

European Commission Approves Roche’s Lunsumio Subcutaneous For Adults With Relapsed Or Refractory Follicular Lymphoma After Two Or More Prior Therapies

EU grants conditional approval for Roche’s subcutaneous Lunsumio, offering faster, convenient treatment for relapsed or refractory follicular lymphoma.

Simantini Singh Deo

Pharma Now

Elicio Therapeutics Appoints Marc J. Wolfgang As Chief Technology Officer, Bringing 30+ Years Of Biopharma Leadership In Cell Therapy, RNA Medicines, And Biologics

Elicio appoints Marc J. Wolfgang as CTO to strengthen manufacturing and CMC strategy ahead of key ELI-002 7P milestones.

Simantini Singh Deo

Pharma Now

Libtayo® Gains EU Approval For Adjuvant Use In CSCC Patients At High Risk Of Recurrence, Offering First Immunotherapy Option Post-Surgery And Radiation

EU approves Libtayo as adjuvant therapy for high-risk CSCC, reducing recurrence risk and expanding its immunotherapy reach.

Simantini Singh Deo

Pharma Now

Regeneron Secures FDA Approval For EYLEA HD In RVO With Extended Dosing Backed By QUASAR Trial Data

FDA approves EYLEA HD for RVO, offering extended dosing flexibility and reduced injection burden for retinal disease patients.

Vaibhavi M.

Pharma Now